
Quest Diagnostics (DGX) Stock Forecast & Price Target
Quest Diagnostics (DGX) Analyst Ratings
Bulls say
Quest Diagnostics is poised for strong growth in the upcoming years as their core trends, including revenue, adjusted EPS, and AOI, continue to surpass expectations. The company's recent partnerships, such as the FMS and Corewell deals, are expected to drive significant revenue growth in 2026. Additionally, the company's strong performance in the physician channel, with high single-digit growth and expanded health plan access, provides potential for continued volume growth. Despite potential headwinds, such as weather and increased investment, DGX maintains a strong financial position with solid cash flow and a healthy balance sheet.
Bears say
Quest Diagnostics is poised for growth with strong first quarter results, beating both top and bottom-line estimates and increasing guidance for FY26. With strong organic volumes and growth in Advanced Diagnostics, as well as investments in AI and automation, the company is well-positioned for future success. Despite solid cash flow and a strong M&A/partnership pipeline, the negative outlook remains due to potential challenges in the healthcare industry such as potential regulation changes and competition from emerging companies.
This aggregate rating is based on analysts' research of Quest Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Quest Diagnostics (DGX) Analyst Forecast & Price Prediction
Start investing in Quest Diagnostics (DGX)
Order type
Buy in
Order amount
Est. shares
0 shares